Format

Send to

Choose Destination
Dermatol Clin. 2011 Jan;29(1):1-8. doi: 10.1016/j.det.2010.09.006.

Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.

Author information

1
Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. douglas.walsh@afrims.org

Abstract

Buruli ulcer (BU), caused by the environmental organism Mycobacterium ulcerans and characterized by necrotizing skin and bone lesions, poses important public health issues as the third most common mycobacterial infection in humans. Pathogenesis of M ulcerans is mediated by mycolactone, a necrotizing immunosuppressive toxin. First-line therapy for BU is rifampin plus streptomycin, sometimes with surgery. New insights into the pathogenesis of BU should improve control strategies.

PMID:
21095521
DOI:
10.1016/j.det.2010.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center